Mindrank AI completed a $52 million Series B round to advance MDR-001, its AI-discovered oral GLP-1 receptor agonist in Phase III trials for obesity in China. The company said funding will support scaling its drug discovery engine and pushing forward its clinical and preclinical pipeline. The financing adds momentum to the effort to convert obesity medicines from injections to oral formulations—where convenience, dosing adherence, and patient preference could drive adoption. Mindrank also indicated additional IND clearances across China and the U.S., with more preclinical candidates nominated. For the broader market, the raise reinforces how GLP-1 innovation remains a top capital priority, with investors backing multiple approaches—delivery formats and discovery methods included—in parallel.